COMMUNIQUÉS West-GlobeNewswire

ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
29/04/2024
This publication, authored by leading experts in inflammasome-mediated inflammation and neurology at University of Miami Miller School of Medicine, demonstrates that multiple inflammasome triggers (NLRP1 and pyrin) [...]
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
29/04/2024
- Top-line Results Expected in the Second Half of 2024 - PURCHASE, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing [...]
OJEMDA™ (tovorafenib) Now Available from Onco360 for the Treatment of Patients Six Months of Age and Older with Relapsed or Refractory Pediatric Low-Grade Glioma (LGG) Harboring a BRAF Fusion or Rearrangement, or BRAF V600 Mutation
29/04/2024
LOUISVILLE, Ky., April 29, 2024 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Day One Biopharmaceuticals for OJEMDA™ (tovorafenib), which [...]
Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024
29/04/2024
DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for [...]
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
29/04/2024
Extended follow-up will include safety, kallikrein reduction and attack rate data, including number of patients who continue to be completely attack free through the latest follow-up Intellia to host investor webcast on [...]
Streamline Health® Expands eValuator™ Footprint With Existing Client
29/04/2024
Following an efficient implementation process, a leading Florida-based healthcare provider is expanding its footprint and utilization of eValuator Atlanta, GA, April 29, 2024 (GLOBE NEWSWIRE) -- Streamline Health [...]
Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024
29/04/2024
CELEBRATION, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, Zevra’s President and [...]
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
29/04/2024
– New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron – MELBOURNE, Australia and SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“ [...]
Kraig Biocraft Laboratories Reports Signing Landmark Agreements in South East Asia
29/04/2024
ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company"), announces today that it has signed key agreements with the Lam Dong Agro-Forestry Research Experiment [...]
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
29/04/2024
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and certain diabetic eye [...]
George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director
29/04/2024
George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director London, UK 29 April 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet need in the treatment [...]
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
29/04/2024
Boston (April 29, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that on [...]
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
29/04/2024
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious [...]
FibroGen to Report First Quarter 2024 Financial Results
29/04/2024
SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on Monday, May 6 after the market close. FibroGen will also conduct a conference call on [...]
Breckenridge Brewery Introduces New West Coast Style IPA ‘Ridge Runner’
29/04/2024
The Perfect Beer for Toasting The Trail Less Traveled LITTLETON, Colo., April 29, 2024 (GLOBE NEWSWIRE) -- Breckenridge Brewery (“Breck Brew”) a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), is [...]
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
29/04/2024
CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc . (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment of Mary Kay [...]
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
29/04/2024
First-Ever Open IND for Prime Editing Technology PM359 is Prime Medicine’s Ex Vivo Product Candidate Designed to Correct a Prevalent Disease-Causing Mutation of CGD Initial Data Expected in 2025 CAMBRIDGE, Mass., April [...]
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
29/04/2024
EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the appointment of [...]
Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
29/04/2024
THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2024 financial results on Thursday, May 2, 2024 after the markets close. Management [...]

Pages